Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Federal Realty Investment Trust

Kellogg

Texas Instruments

I love my dividend stocks, and since I'm still not retired, market downturns let me buy more of what I own as I reinvest my dividends.

Stock Market Sell-Off: How I'm Continuing to Make Passive Income

Medtronic is a global leader in medical technology. The company functions in four operating segments: Cardiac & Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. It is a stellar free cash flow generator with a strong Dividend Cushion ratio, though the outlook for the company's margin expansion opportunities has been diminished somewhat.

Undervalued Medtronic Sports Solid Dividend Growth Prospects

DUBLIN , Aug. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2023 on Tuesday, August 23, 2022. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its first quarter of fiscal year 2023

Intuitive Surgical

Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.

Are Medtronic And Intuitive Surgical Poised For Big Growth?

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Caterpillar

Cincinnati Financial

Chevron

Leggett & Platt

Realty Income Corp

Stanley Black & Decker

V.F.

Walgreens

Exxon Mobil

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of August 4, 2022 represented all eleven Morningstar Sectors. Broker estimated top-ten net gains ranged 14.54%-40.69% topped by XOM & SWK.

Buy 4 S&P 500 August Dog Days Dividend Aristocrats

Medical device maker Medtronic (NYSE: MDT) stock is trading down (-14%) for the year.

Medtronic Stock Keeps Ticking Forward

Bausch Health Companies Inc

Bausch + Lomb Corp

Meihua International Medical Technologies Co

Tenon Medical Inc

Virax Biolabs Group Ltd

At least one group is bullish about the outlook for the medtech industry: venture capitalists.

Investors May Want to Follow Progress of VC-Backed Medtechs

Advanced technology in spinal surgery is helping the company build its case in a fast-growing market.

How Medtronic Is Strengthening Its Robotics Portfolio

Medtronic stock has been battered over the past year over several headwinds, including considerable supply chain challenges. However, we believe it has formed a significant long-term bottom. MDT has a robust long-term uptrend. It has rewarded long-term investors who bought on significant dips over time. Our analysis is flashing those robust buy signals.

Medtronic: Flashing Robust Buy Signals, Buy Hand Over Fist (Technical Analysis)

Medtronic is the world's largest pure-play medical device company. It is a dividend aristocrat, conservatively financed and well diversified. It seems like a great long-term investment. The company piqued my interest because of its diabetes portfolio, however, I found that managerial missteps left Medtronic in a weak position compared to Abbott and Boston Scientific.

Don't Buy Medtronic For Its Diabetes Franchise

With the market off its peak, these three stocks are worth a close look while they are on the sale rack.

These 3 Stocks Are Timely Buys Amid the Market Sell-off

Target

The highest-yielding stock on this list pays more than 4%.

3 High-Yielding Dividend Aristocrats to Buy Right Now

Black Hills

Clorox

Fresenius Medical Care

MDU Resources Group

Altria

National Fuel Gas

Novartis

Northwest Natural Gas

Philip Morris

Fears of a recession are mounting, with BAC and Deutsche Bank now forecasting a mild downturn in 2023. A recession could even begin by December 2022. Even without a recession Morgan Stanley is confident stocks have 10% lower to fall. If we get a mild recession, stocks could fall 25% more and in a severe recession, 35%.

11 High-Yield Dividend Aristocrats Perfect For The Coming Recession

Shares of Medtronic have reached their 52-week low this week. Medtronic's dividend yield is almost 3%, making it an attractive dividend growth prospect.

At Its 52-Week Low, Medtronic Is A Buy

Additional +80 GI Genius™ units to be donated for a total of 133 to 62 facilities that primarily serve communities with low screening rates or where access to the technology is not currently available Grady Memorial Hospital in Atlanta, Georgia is the first site to receive GI Genius modules through Medtronic's Health Equity Assistance Program DUBLIN , July 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced they are expanding the Medtronic Health Equity Assistance Program for colon cancer screening in medically underserved communities across the United States, with support from Amazon Web Services's (AWS) Health Equity Initiative. The GI Genius units provided as part of the program have increased from 50 to 133 systems being placed at 62 facilities.

Medtronic expands Health Equity Assistance Program for colon cancer screening with support from Amazon Web Services; Completes first installation of donated GI Genius™ intelligent endoscopy modules

Diageo

Disney

Digital Realty Trust

Ryanair Hlds

Toyota Motor

Looking for a bargain? Bottom-fishing investors may want to check out these stocks trading at a 52-week lows, or within 5% of that floor.

7 Stocks Trading at a 52-Week Low Worth Buying Now

Powered by a database of over 10,000 surgical cases, Medtronic continues to evolve the UNiD™ platform to help surgeons plan procedures, personalize care for their patients and predict post-operative spinal compensation   DUBLIN , July 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its UNiD™ Spine Analyzer v4.0 planning platform, which includes a new Degen Algorithm for degenerative spine procedures. The algorithm leverages machine learning to help surgeons plan and personalize procedures for patients undergoing lower lumbar spine surgery and predicts spinal compensation mechanisms six months after the operation.

Medtronic receives FDA clearance for next-generation UNiD™ Spine Analyzer with degenerative spine surgery predictive model

Johnson & Johnson

TotalEnergies SE

Amid an ailing stock market, shareholders wonder what the best mutual funds do that their own funds are not. And what are the best stocks to buy now?

Smart Buys, Sells That Make This American Century Fund Shine

Partnership underscores Medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment  CathWorks' FFRangio® System provides diagnostic and physiologic information through artificial intelligence to potentially disrupt traditional FFR and revolutionize the management of coronary artery disease DUBLIN and KEFAR SAVA, Israel , July 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. As part of the agreement, Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks' FFRangio® System in the U.S., Europe and Japan, where it is commercially available.

Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition

Occidental Petroleum

Following these legendary investors could help your portfolio weather any storm.

3 Stocks the World's Best Investors Are Buying Now

Emerson Electric

General Dynamics

Genuine Parts

McDonald's

Procter & Gamble

Sherwin-Williams

I want to make certain that the Dividend Aristocrat I recommend will provide me with more than dividends. I want stock price appreciation as well.

S&P 500's Best Dividend Aristocrat Stocks To Consider

Novo Nordisk

These stocks are worth buying whether or not a recession is coming.

2 Safe Stocks That Can Survive Any Downturn

News for Medtronic Stock (MDT)